and non-invasive angiogenic strategy. Tohoku J Exp Med 219 : 1–9, 2009.
2) Nishida T, et al : Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 110 : 3055–3061, 2004.
3) Fukumoto Y, et al : Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 17 : 63–70, 2006.
4) Kikuchi Y, et al : Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 74 : 589–591, 2010.
5) Uwatoku T, et al : Extracorporeal cardiac shock wave therapy ameliorates left ventricular remodeling after acute myocardial infarction in pigs. Coron Artery Dis 18 : 397–404, 2007.
6) Ito Y, et al : Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. Coron Artery Dis 21 : 304–311, 2010.
7) Oi K, et al : Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits. Tohoku J Exp Med 214 : 151–158, 2008.

Original Article

Nitroglycerin-mediated vasodilatation of the brachial artery may predict long-term cardiovascular events irrespective of the presence of atherosclerotic disease

Daijirou Akamatsu, Akira Sato, Hitoshi Goto, Tetsuo Watanabe, Munetaka Hashimoto, Takuya Shimizu, Hirofumi Sugawara, Hiroko Sato, Yoshiyuki Nakano, Teiji Miura, Tsutomu Zukeran, Fukashi Serizawa, Yow Hamada, Ken Tsuchida, Ichiro Tsuji, and Susumu Satomi

Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai, Japan

Aim: Nitroglycerin-mediated vasodilatation (NMD) provides insight into the NTG-induced bioactivity of smooth muscle. It is plausible that in dysfunctional smooth muscle cells, the response to nitroglycerin may become blunted. The relationship between impaired brachial artery NMD and subsequent cardiovascular events is not well established.

Methods: We examined brachial artery flow-mediated dilatation (FMD) and NMD using ultrasound in 93 subjects (71±7 years, including 26 with peripheral artery disease (PAD), 37 with aortic aneurysms, 10 with PAD complicated with aneurysms, and 20 without evident arterial disease). Brachial artery responses to hyperemia and nitroglycerin were measured every minute after cuff deflation and nitroglycerin administration. Time courses of vasodilatation were assessed and maximal FMD and NMD were measured.

Results: The time courses in response to NTG were sigmoidal and maximal diameter reached 7.2±1.6 minutes after NTG was administered sublingually. The mean FMD was 2.3±2.0% and the mean NMD was 17.6±7.1%. Subjects were prospectively followed for an average of 47±13 months. Eighteen subjects had an event during follow-up; events included myocardial infarction (five), unstable angina pectoris (four), stroke (two), aortic dissection (one), ruptured aortic aneurysm (three), symptomatic abdominal aortic aneurysm (two), and lower limb ischemia requiring revascularization (one). NMD and FMD were significantly lower in subjects with events than in those without an event. In a Cox proportional-hazards model, lower FMD as well as lower NMD independently predicted future cardiovascular events.

Conclusion: Brachial artery nitroglycerin-mediated vasodilatation may add information to conventional risk stratification.

J Atheroscler Thromb, 2010; 17:1266-1274.

Key words; nitroglycerin-mediated vasodilatation, flow-mediated vasodilatation, endothelial dysfunction, smooth muscle dysfunction

Introduction

Atherosclerosis is a progressive disease that initially involves endothelial dysfunction, the accumulation and peroxidation of intimal lipids, and the release of inflammatory cytokines and growth factors, resulting in vascular smooth muscle cell proliferation and collagen matrix production. Intensified inflammatory activity may lead to local proteolysis, plaque rupture, and thrombus formation, resulting in ischemia and infarction[1, 2]. There is currently increasing interest into a new method for predicting cardiovascular

Address for correspondence: Daijirou Akamatsu, Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku Sendai, 980-8574 Japan
E-mail: ddaa1025@m.tains.tohoku.ac.jp
Received: February 13, 2010
Accepted for publication: July 20, 2010

events. Some researchers have reported that endothelial dysfunction predicts cardiovascular events[3-9]. Endothelial function is non-invasively assessed by using flow-mediated vasodilatation (FMD), to determine the endothelium-dependent vasodilatory response in the brachial artery[7, 10-12]. Impaired FMD has been suggested as a prognostic tool to predict future cardiovascular events[3-5, 13], and so FMD may be a marker of cardiovascular atherosclerosis.

The brachial ultrasound test to determine vascular function also assesses the artery's vasodilatory response to nitroglycerin (NTG), which has direct effects upon the smooth muscle producing a endothelium-independent vasodilatation[14]. Weaker responses to nitroglycerin-mediated vasodilatation (NMD) have been observed in patients with coronary heart disease (CHD)[15, 16] and in subjects with CHD risk factors[17]. Recently, a weaker response to NMD, not FMD, has been associated with the presence and quantity of calcium within the coronary artery in asymptomatic adults. This suggests NMD to be a marker of coronary anatomical abnormality[18].

The power of brachial NMD to be used as a clinical marker of cardiovascular disease is unclear. Our previous study showed that brachial responses to NTG reached a maximal limit approximately 7 minutes after the administration, and that NMD correlated with atherosclerotic risk factors in patients displaying evidence of atherosclerosis[19]. The current study was undertaken to investigate whether NMD can provide prognostic information on cardiovascular disease.

Methods

Study population

A total of 93 subjects including 73 patients with justifiable evidence of atherosclerosis and 20 without evidence of peripheral artery disease (PAD) or aneurysm were studied using brachial ultrasound tests. The 73 patients comprised 26 with PAD, 37 displaying on abdominal or thoracic aortic aneurysm and the remaining 10 exhibiting complicated PAD with an aortic aneurysm (**Table 1**). The subjects with atherosclerosis were all ambulatory, and all agreed to be enrolled in this study. All PAD patients displayed symptoms and voluntarily checked in to our hospital to receive the appropriate treatment. PAD was diagnosed by duplex scanning or computed tomography (CT) based on an ABI <0.9. An aneurysm was diagnosed when localized dilatation of the aorta was at least 50% larger than an adjacent normal portion detected by either ultrasonography or CT. At the time of vascular evaluation, none of the subjects displayed decompensated heart failure, glaucoma, ischemic gangerene, malignant neoplasma, or evidence of hepatic, renal or inflammatory disease. The 20 adults without evidence of arterial disease were chosen from the general physical examination list and all agreed to be enrolled in this study. They all had an ABI >0.9, normal electrocardiogram, normal chest X-ray, and normal ultrasonographic results from the abdominal aorta to the iliac artery, as well as no history of previous cardiovascular events, or the taking of vasoactive medications. This investigation was approved by the Tohoku University ethics committee, with all participants giving written consent.

Table 1. Baseline Characterisitics

Age	71 ± 7
Sex, female/male	7/86
Aortic Aneurysm	37 (40)
PAD	26 (28)
PAD complicated with aneurysm	10 (11)
Hypertension	59 (63)
Dyslipidemia	20 (22)
Diabetes mellitus	25 (27)
Smoking history	70 (75)
Previous history of CAD	18 (19)
Previous history of stroke	14 (15)
Atrial fibrillation	5 (5.4)
Medications at entry	
ACE inhibitors	26 (28)
Calcium antagonists	49 (53)
ARBs	20 (22)
Statins	13 (14)
Insulin	7 (7.5)
Oral hypoglycemic agents	5 (5.4)
NO donors	13 (14)

The numbers in parentheses represent percentages.
ACE: angiotensin-converting enzyme
ARB: angiotensin 2 receptor blocker

Brachial ultrasound tests

After an overnight fast (14 hours), FMD and NMD were measured using an ultrasound (Aplio SSA-700A 5-12-MHz linear array transducer, Toshiba) as described previously[10, 11]. Briefly, the brachial artery was scanned in longitudinal sections 2-10 cm above the elbow (control scan) after 15 min of rest in the supine position. The depth and gain settings were optimized to identify the anterior and posterior intimal interfaces between the lumen and vessel wall. Hyperemia was induced by inflating a forearm blood pressure cuff 50 mmHg above the systolic pressure for

5 minutes before deflating it. The vasodilator response to hyperemia was recorded for 5 minutes after deflation. Following at least 10 minutes' rest, a further control scan was performed and recorded. A single 300-μg dose of NTG was administered sublingually. Upon the NTG administration, a drop of water was poured over the tablet and the drug solution checked, as dissolution was found to be delayed in older patients due to dentures or dryness of the mouth[20]. Thereafter, the vasodilator response to NTG was recorded for 15 minutes.

Measurements were recorded at end-diastole, coinciding with the R-wave viewed on ECG. Mean diameter measurements were calculated from three different cardiac cycles. FMD and NMD were expressed as a percent change relative to the diameter before cuff inflation and before drug administration, respectively. Brachial artery responses to reactive hyperemia and NTG were measured every minute after cuff deflation and NTG administration. Maximal diameter responded to hyperemia and NTG was used to calculate FMD and NMD. Brachial diameter from three minutes after NTG administration was used for NMD3. The intra-observer variability for repeated measurements of resting arterial diameter was 0.02 ± 0.01 mm, variability in FMD was 0.49 ± 0.27 (%), and variability for NMD was 0.44 ± 0.34 (%). Brachial intima-media thickness (brachial IMT) was also measured as described[21]. The same segment of the brachial artery used to analyze vasodilatory response was measured for brachial IMT. The scan was focused on the posterior wall, and eight measurements were taken at end-diastole, coinciding with the R-wave, at even intervals. The average of these measurements was used as the mean brachial IMT for comparative analysis. Before the brachial ultrasound test commenced, a venous blood sample was taken, and the plasma was separated from the blood cells by centrifugation. The total plasma homocysteine level was determined using high-pressure liquid chromatography (SRL, Tokyo, Japan). The serum concentration of advanced glycation end products (AGEs) was measured with an enzyme-linked immunosorbent assay (SRL, Tokyo, Japan). Serum triglyceride, and total cholesterol levels were also measured using commercially available kits.

Follow-up and cardiovascular events

The majority of patients visited the outpatient clinic periodically. To improve long-term follow-up, a questionnaire was mailed to primary physicians and telephone interviews were undertaken to assess the incidence of cardiovascular events. All information regarding cardiovascular events was validated by obtaining source data, including hospital records, death certificates, and any other original documents available.

The following cardiovascular events were assessed during long-term follow-up. Sudden cardiac death, fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, unstable angina, coronary revascularization procedures, symptomatic or ruptured aortic aneurysm, and newly developed aortic dissection or symptomatic aortoiliac occlusive disease were defined as cardiovascular events. Myocardial infarction was defined as an increase in creatine kinase and ST elevation and coronary angiography. Unstable angina was defined as chest pain associated with ischemic ECG changes and coronary angiography. Ischemic stroke was defined as evidence of a stroke without intracranial hemorrhage determined by brain imaging scans. Peripheral bypass revascularization was defined as the need for surgical revascularization of a de novo stenosis or occlusion of peripheral arteries. In patients with aortic aneurysm, the aneurysm diameter was assessed by ultrasonography every 3 months and by CT every 6- 12 months. A symptomatic or ruptured aneurysm and/or an aneurysm more than 5 cm in diameter were recommended for surgery.

Statistical analysis

Data are expressed as the mean $\pm$SD. Comparisons were made using the Student's t test if data were normally distributed; otherwise, they were analyzed using a nonparametric, Mann-Whitney *U*-test. Categorical variables were compared with the χ^2 test or Fisher's exact probability test. Univariate associations between variables were analyzed by calculating the Pearson's correlation coefficient. Cumulative event numbers were estimated using Kaplan Meier survival curves for categorical variables. Each measured value was altered to a categorical value based on the median. Probability values were determined by the use of the log-rank statistic. A Cox proportional-hazards model was used to examine whether FMD, NMD and NMD3 were each separately predictive of cardiovascular events. Data was first assessed using the Kaplan Meier survival curves for variables, the variables were then entered into the model based on the selection criteriaun of a log-rank probability value $\leqq 0.10$. Based on this, the following variables were tested: age, brachial diameter, suffering PAD and/or aneurysm, brachial IMT, plasma total homocysteine, serum levels of AGEs, triglyceride, total cholesterol, medications at entry (angiotensin-converting enzyme inhibitors, angiotensin 2 receptor blockers, calcium antagonists, Statins, NO donor) as well as a previous history of CAD, stroke, hypertension, atrial fibrillation, hyper-

lipidemia and diabetes mellitus. A p value of <0.05 was considered significant. All statistical analysis was performed using SAS software.

Results

The mean age of participants was 71 ± 7 (range 51-86) years and the mean follow-up period was 47 ± 13 (range, 6-63; median, 49.8) months. A total of 59 (63.4%) participants were hypertensive and 14 (15.1%) had previously suffered a stroke. Eighteen (19.4%) participants had a previous history of CAD; among these, 13 subjects received percutaneous coronary intervention (PCI) for angina pectoris (AP), one subject received coronary artery bypass grafting (CABG) for AP, two subjects received PCI for acute myocardial infarction (AMI) and two subjects received CABG for AMI. Five subjects suffered atrial fibrillation and three subjects received anticoagulant therapy.

The mean FMD was 2.3 ± 2.0% (range −1.2-8.7%), mean NMD was 17.6 ± 7.1% (range 2.6-37.1%), and mean NMD3 was 8.4 ± 5.7% (range −0.6-24.8%). FMD was directly correlated with NMD ($r=0.459$, $p<0.001$) and NMD3 ($r=0.351$, $p<0.001$).

Maximal diameter was reached at 7.2 ± 1.6 (range 4-12) minutes after 0.3 mg of NTG was administered sublingually. The time courses in response to NTG were sigmoidal (**Fig. 1**), displaying a gradual increase from 0- 2 minutes, then rapidly increasing to approximately 5 minutes, again followed by a gradual increase.

FMD (2.1 ± 1.9% versus 3.1 ± 2.4%, $p=0.06$) and NMD3 (7.9 ± 5.3% versus 10.5 ± 6.6%, $p=0.07$) were lower but not significantly different when comparing subjects with established arterial disease to those without arterial disease at entry. NMD was similar between the two groups (17.4 ± 7.3% versus 18 ± 6.3%, $p=0.73$).

During the follow-up, there were 18 new cardiovascular events including five participants suffering MI (three of which died), four with unstable angina pectoris (all four underwent coronary revascularization), one operated on for ruptured abdominal aortic aneurysm (AAA), two operated on for symptomatic AAA, two with a ruptured thoracic aortic aneurysm (both of when died), one thoracic aortic dissection (Stanford A, fatal), two non-fatal strokes, and one displaying new onset lower limb ischemia that underwent revascularization. Among these, the one nonfatal unstable angina pectoris patient and the one patient that developed lower limb ischemia developed these events despite no sign of vascular disease at the beginning of the study. In addition, three participants died



Fig. 1.

Time course of brachial artery responses to NTG. The time courses are sigmoidal curves.

of gastric cancer (23, 25 and 14 months after brachial tests), and two died of pneumonia (6 and 48 months after tests).

FMD, NMD and NMD3 were all significantly lower in the Event (+) group than Event (−) group. Total levels of homocysteine, AGEs, and highly sensitive CRP did not differ significantly between the two groups (**Table 2**).

Multivariate analysis

In the univariate analysis using Kaplan-Meier curves, a previous history of coronary artery disease ($p=0.006$) was found to be significantly associated with the occurrence of cardiovascular events. Although not significant, a history of stroke ($p=0.07$) had a tendency to be associated with occurrence of the events. A history of smoking ($p=0.877$), hypertension ($p=0.678$), hyperlipidemia ($p=0.492$), diabetes mellitus ($p=0.818$), or atrial fibrillation ($p=0.11$), suffering from an arterial disease including PAD and/or aortic aneurysm ($p=0.216$), and having a larger brachial diameter (>4.3 mm, $p=0.20$), larger brachial IMT (>0.45 mm, $p=0.942$), higher total homocysteine levels (>11.75 nmol/ml, $p=0.951$), or higher serum levels of AGEs (>2.8 mU/ml, $p=0.430$), higher levels of hs-CRP (>0.98 mg/L, $p=0.121$), higher levels of total cholesterol (>220 mg/dl, $p=0.253$), and higher levels of TG (>150 mg/dl, $p=0.818$) were not associated with a poor outcome. Regarding medications at entry, using NO donors was associated with occurrence of the events ($p=0.039$) but such a relationship was not observed for other drugs. Participants with lower levels of NMD (<18.6%, $p<0.001$) differed significantly from those with higher levels of NMD (>18.6%) (**Fig. 2**). Participants with lower levels of

Table 2. Clinical characterisitics of subjects with cardiovascular events and those without event

	Event (+) (n = 18)	Event (−) (n = 75)	p-value
Age	73 ± 7.4	71 ± 6.9	0.09
Sex, female/male	18/0	68/7	0.18
Smoking history	14	56	0.78
Body mass index (kg/m^2)	22.9 ± 3.3	24.2 ± 3.3	0.21
Without evident arterial disease	2	18	0.23
Aneurysm	8	29	0.65
PAD	6	20	0.57
PAD complicated with aneurysm	2	8	0.95
Hypertension	12	47	0.75
Dyslipidemia	5	15	0.47
Diabetes mellitus	4	21	0.61
Previous history of CAD	7	11	0.02
Previous history of stroke	5	9	0.09
Atrial fibrillation	2	3	0.25
Brachial diameter (mm)	4.5 ± 0.6	4.3 ± 0.7	0.12
FMD (%)	1.4 ± 1.5	2.5 ± 2.0	0.04
NMD (%)	12 ± 6.4	18.9 ± 6.6	0.0006
NMD3 (%)	4.1 ± 4.4	9.5 ± 5.5	0.0001
Brachial IMT (mm)	0.46 ± 0.07	0.45 ± 0.08	0.53
Total cholesterol (mg/dL)	200 ± 35	194 ± 36	0.52
Triglycerides (mg/dL)	122 ± 59	118 ± 64	0.73
hs-CRP (mg/L)	2.51 ± 2.06	2.31 ± 3.89	0.16
Total homocysteine (nmol/mL)	12.5 ± 3.3	12.2 ± 3.8	0.59
AGEs (mU/ml)	2.9 ± 0.66	2.8 ± 0.63	0.31
Medications at entry			
ACE inhibitors	5	21	0.98
ARBs	3	17	0.58
Calcium antagonists	11	38	0.42
Statins	4	9	0.26
NO donors	5	8	0.06

Data are expressed as the mean ± S.D.
ACE : angiotensin-converting enzyme; ARB : angiotensin 2 receptor blocker



Fig. 2.

Kaplan-Meier event-free survival curves for participants. The left panel displays event-free survival classified on the basis of median NMD (=18.6%). Subjects with a value higher than the media differed significantly from those with a value lower than the median (p < 0.001). The right panel displays event free-survival classified on the basis of median FMD (1.9%). Subjects with a value higher than the median differed significantly from those with a value lower than the median (p = 0.012).

Table 3. Univariate and multivariate analyses for cardiovascular events

variables	*p*-value of log-rank test	Multivariate cox regression analysis							
		Model 1		Model 2		Model 3		Model 4	
		RR (95%CI)	*p*	RR (95%CI)	*p*	RR (95%CI)	*p*	RR (95%CI)	*p*
age	-	1.0 (0.95-1.1)	0.458	1.1 (0.99-1.2)	0.097	1.0 (0.95-1.1)	0.45	1.1 (0.98-1.2)	0.16
previous CAD	0.006	0.3 (0.1-1.3)	0.112	0.2 (0.04-0.89)	0.035	0.7 (0.2-3.1)	0.63	0.18 (0.04-0.9)	0.03
previous stroke	0.07	0.4 (0.1-1.2)	0.1	0.7 (0.23-1.9)	0.441	0.6 (0.2-1.7)	0.3	0.57 (0.2-1.7)	0.3
using NO donor	0.039	1.3 (0.3-5.6)	0.716	2.7 (0.5-13)	0.233	0.5 (0.1-2.4)	0.41	2.8 (0.6-14)	0.2
FMD	0.012	4.3 (1.4-13.0)	0.009	-	-	-	-	2.1 (0.6-6.6)	0.23
NMD	0.001>	-	-	10.4 (2.6-42)	0.001	-	-	7.1 (1.6-32)	0.01
NMD3	0.003	-	-	-	-	4.5 (1.4-14)	0.01	-	-

A log-rank probability value ≦0.1 was used as the criterion for entry into the multivariate analysis.

FMD (<1.9%) and NMD3 (<8.2%) also differed significantly from those with higher levels of FMD (>1.9%, $p=0.012$, **Fig. 2**) and NMD3 (>8.2%, $p=0.003$).

A multivariate Cox regression analysis was used to examine whether FMD, NMD and NMD3 were each separately predictive of cardiovascular events. By the selection criteriun of a log-rank probability value ≦0.10, a previous history of coronary artery disease, previous stroke, and using NO donors were entered into the model in addition to FMD, NMD and NMD3. As shown in **Table 3**, lower NMD, lower NMD3 and lower FMD each separately predicted cardiovascular events. When NMD and FMD were entered into the same model (**Table 3**, model 4), NMD significantly predicted events, but FMD was not associated with events. The same results were obtained when 20 subjects without evidence of PAD or aneurysm were excluded.

A scatter graph of NMD v.s FMD is shown in **Fig. 3**. Thirteen of 18 subjects with cardiovascular disease were distributed under the line of median FMD ($n=48$, 13/48, 27%). Fifteen were distributed under the line of median NMD ($n=47$, 15/47, 32%). Twelve cases of cardiovascular disease were framed by median FMD and median NMD ($n=31$, 12/31, 39%).

When the subjects taking NO donors were excluded ($n=80$), 13 subjects had an event during follow-up. NMD (19.4±6.5 versus 11.7±6.6%, $p=0.001$) and NMD3 (9.9±5.5 versus 3.9±4.6%, $p<0.001$) were significantly lower in subjects with an event than in those without an event. However, FMD was not significantly lower in subjects without an event (2.5±2.1 versus 1.6±1.6%, $p=0.20$). A previous history of CAD ($p<0.001$), NMD ($p=0.011$) and NMD3 ($p=0.004$) were significantly associated



Fig. 3.

Scatter graph of NMD v.s FMD. Twelve of 18 subjects suffering cardiovascular events were distributed within the lower FMD (< 1.9%) and lower NMD (<18.6%) group. Thirty-one out of 93 subjects were distributed within the lower FMD (<1.9%) and lower NMD (<18.6%) group.

with an event in the univariate analysis, although, lower FMD did not significantly differ from higher FMD ($p=0.16$). In the multivariate analysis, NMD ($p=0.003$) and NMD3 ($p=0.03$) were each separately associated with cardiovascular events.

In addition, we excluded aortic diseases from the endpoint analysis. Twelve subjects developed events. In the univariate analysis, a previous history of CAD ($p=0.01$), a previous history of CVD ($p=0.04$), using NO donors ($p=0.002$), FMD ($p=0.02$), NMD ($p=0.007$), and NMD3 ($p=0.02$) were associated with cardiovascular events. In the multivariate analysis, NMD ($p=0.002$) predicted the events, but FMD ($p=0.07$) and NMD3 ($p=0.05$) were not significantly associated with the events.

Discussion

In this small, prospective study, nitroglycerin-mediated vasodilatation was found to predict cardiovascular events, in subjects with a mean age of 71 years including patients with atherosclerosis and healthy participants displaying no evidence of atherosclerotic disease. Impaired FMD was also associated with an increased risk of cardiovascular events; however, NMD was rather closely associated with such a risk. FMD is a method used to measure brachial smooth muscle dilation induced by endogenous nitric oxide, while NMD is induced by stimulation with exogenous nitric oxide[14]. Endothelial function is important in FMD as shear stress stimulates NO synthesis, dilating surrounding vascular smooth muscle[10], while NMD provides insight into NTG-induced bioactivity of the smooth muscle, inducing relaxation[14]. However, a comparison of FMD does not indicate true endothelial function when downstream smooth muscle reactivity differs between individuals. Hence, the relationship between FMD and NMD would be complementary. Although FMD and NMD are directly correlated, twelve of 18 subjects suffering cardiovascular events distributed within the region framed by the lower FMD($<1.9\%$) and lower NMD($<18.6\%$) value in the scatter graph, so a parameter combining FMD and NMD may serve as a more effective predictor of cardiovascular events.

Previously published data concerning the association between brachial ultrasound examinations and cardiovascular events suggest that FMD, and not NMD, was associated with incidents of cardiovascular events[6, 7], while some studies either did not measure NMD[4, 5] or did not provide sufficient statistical data[3]. These discrepancies may due to technical differences between research groups, and differences between test subjects. Some studies calculated NMD at 3 or 4 minutes after NTG administration[6], or measured vessel diameter between the media and adventitia. We measured the brachial diameter between the lumen and vessel wall, and recorded the entire time course following NTG administration. Over the time course, the brachial artery responded with a sigmoidal pattern, and reached maximal diameter at 7.2 ± 1.6 minutes. NMD3 is suggested to underestimate the extent of vasodilatation induced by the sublingual application of NTG; however, NMD3 was able to predict cardiovascular events in the current study. Our previous report suggested that NMD was associated with atherosclerotic risk factors, but that NMD3 displayed no such association[19]. NMD displays the dilative potency of NTG, while NMD3 provides a measure of the speed of response to NTG, or provides a limited measure of dilatation. In our population, NMD3 or NMD4 would be poorly reproducible as 3- 4 minutes post-NTG treatment the brachial artery is only midway through its increase in diameter as shown in **Fig. 1**.

NMD was similar between those with and without arterial disease. Long-term use of medication may have an influence, as most patients with established arterial disease were taking antihypertensives or antiplatelet agents or receiving treatment for hyperlipidemia for long periods.

FMD and NMD were significantly lower in individuals that experienced cardiovascular events than in the non-event group. The reason why NMD predicted cardiovascular events remains speculative. Some studies have demonstrated NMD to be associated with high blood pressure[13], diabetes mellitus[17], high oxidized LDL expression[21], and great carotid IMT[21]. NMD reflects NTG-induced dilatation of the brachial smooth muscle, not mechanical forces limiting the ability of the vessel to relax, as confirmed by the observation that brachial IMT did not significantly correlate with NMD[18]. Smooth muscle cells play a pivotal role in atherosclerosis, and it is plausible that in dysfunctional smooth muscle cells, the response to nitroglycerin may become blunted. Recently, J. Kullo *et al.*[18] suggested the vasodilative response to nitroglycerin, but not FMD, to be associated with the presence and level of coronary atherosclerosis in 441 asymptomatic adults. Although this study was in subjects with subclinical atherosclerosis, an association between coronary atherosclerosis and impaired smooth muscle relaxation in the brachial artery may be evident.

Yeboah *et al.*[5] studied the relationship between impaired brachial FMD and clinical cardiovascular events in 2791 elderly adults (mean age; 78.6 ± 4.4, range; 72 to 98 years). In this study, event-free survival rates for cardiovascular events were significantly higher in subjects with FMD greater than the sex-specific medians than in subjects with FMD less than or equal to the medians, but added only $\approx$ 1% to the prognostic accuracy of the best Cox model. Shimbo *et al.*[4] also studied the relationship between FMD and future cardiovascular events in 842 elderly participants free of stroke or myocardial infarction, and concluded that FMD predicts incidents of cardiovascular events, though its predictive value was not independent of cardiovascular risk factors. These studies suggest that the clinical utility of brachial FMD is very limited in the elderly with diminished FMD. Impaired smooth muscle function may also be the underlying mecha-

nism responsible for the diminished FMD in elderly subjects. There is a need to evaluate the relationship between brachial vascular function (both FMD and NMD) and CVD risk prediction by age group.

NMD and NMD3 were each separately associated with cardiovascular events but FMD was not, when subjects taking NO donors were excluded from the analysis. A previous study showed that GTN induces tolerance to nitrate and endothelial dysfunction[22]. In the present study, long-term use of NO donors would have affected NMD as well as FMD, and lessened the predictive value of FMD when excluding subjects using NO donors.

Our study does have some limitations: it examined male subjects comprising asymptomatic participants drawn directly from the community, almost exclusively. Although the sample group gathered does represent a population of particular interest for the purpose of primary prevention, risk identification and reduction of cardiovascular disease, we cannot rule out sub-clinical coronary atherosclerosis, because not all the subjects underwent coronary angiography at the start of the study. The patients with PAD used in the current study displayed mild atherosclerosis without gangrene, ensuring that the effects of inflammation or infection were excluded. However, this also resulted in deselection of severe or uncontrolled diabetes mellitus. Thus, the results reported here should not be extrapolated to whole populations, or those with low risk or severe atherosclerosis. Although it remains controversial whether atherosclerosis is a causative factor of aneurysms, we included patients with aneurysms because most exhibit risk factors for atherosclerosis. Our sample size is small, but larger study samples may enable diabetes mellitus, hypertension, the presence of PAD and/or aneurysm, dyslipidemia, and higher levels of hsCRP to also become independent predictors of cardiovascular events, as reported in earlier studies[4-6, 23]. Although this study included only Asian subjects, these findings might be applicable to subjects of other ethnicities.

In summary, brachial FMD as well as NMD is an independent predictor of long-term cardiovascular events in subjects with a mean age of 71 years, including patients with atherosclerosis and healthy participants displaying no evidence of atherosclerotic disease. Further research is required to clarify the predictive value of FMD and NMD over various levels of cardiovascular risk factors.

Acknowledgments

The authors thank Yoichi Yoshida for helping to study the healthy control subjects.

References

1) Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J: Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation, 2004; 109: 2617-2625
2) Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126
3) Huang AL, Silver AE, Shvenke E, Schopfer DW, Jahangir E, Titas MA, Shpilman A, Menzoian JO, Watkins MT, Raffetto JD, Gibbons G, Woodson J, Shaw PM, Dhadly M, Eberhardt RT, Keaney JF, Jr., Gokce N, Vita JA: Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol, 2007; 27: 2113-2119
4) Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, Boden-Albala B, Sacco R, Homma S: The association between endothelial dysfunction and cardiovascular outcomes in a population-based multiethnic cohort. Atherosclerosis, 2007; 192: 197-203
5) Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM: Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation, 2007; 115: 2390-2397
6) Gokce N, Keaney JF, Jr., Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA: Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol, 2003; 41: 1769-1775
7) Brevetti G, Silvestro A, Schiano V, Chiariello M: Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation, 2003; 108: 2093-2098
8) Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation, 2001; 104: 191-196\
9) Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000; 101: 1899-1906
10) Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992; 340: 1111-1115
11) Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol, 2002; 39:

257-265
12) Tsuchiya K, Nakayama C, Iwashima F, Sakai H, Izumiyama H, Doi M, Hirata Y: Advanced endothelial dysfunction in diabetic patients with multiple risk factors; importance of insulin resistance. J Atheroscler Thromb, 2007; 14: 303-309
13) Gokce N, Holbrook M, Duffy SJ, Demissie S, Cupples LA, Biegelsen E, Keaney JF, Jr., Loscalzo J, Vita JA: Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension, 2001; 38: 1349-1354
14) Chen Z, Zhang J, Stamler JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A, 2002; 99: 8306-8311
15) Zhang X, Zhao SP, Li XP, Gao M, Zhou QC: Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis, 2000; 149: 19-24
16) Raitakari OT, Seale JP, Celermajer DS: Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis. Am J Cardiol, 2001; 87: 217-219, A8
17) Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, Celermajer DS: Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol, 1998; 32: 123-127
18) Kullo IJ, Malik AR, Bielak LF, Sheedy PF, 2nd, Turner ST, Peyser PA: Brachial artery diameter and vasodilator response to nitroglycerine, but not flow-mediated dilatation, are associated with the presence and quantity of coronary artery calcium in asymptomatic adults. Clin Sci (Lond), 2007; 112: 175-182
19) Akamatsu D, Satou A, Watanabe T, Hashizume E, Gotou H, Satomi S: Smooth muscle dysfunction in patients older than 54 years of age with objective evidence of arteriosclerosis. Eur J Vasc Endovasc Surg, 2007; 34: 639-645
20) Ducharme A, Dupuis J, McNicoll S, Harel F, Tardif JC: Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. Am J Cardiol, 1999; 84: 952-954, A8
21) Jarvisalo MJ, Lehtimaki T, Raitakari OT: Determinants of arterial nitrate-mediated dilatation in children: role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness. Circulation, 2004; 109: 2885-2889
22) Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken-Weckmuller S, Walter U, Reichenspurner H, Meinertz T, Munzel T: Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation, 2002; 105: 1170-1175
23) Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S: An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb, 17: 1-11

Eur J Vasc Endovasc Surg (2011) xx, 1–7

ELSEVIER

Extracorporeal Shock Wave Therapy Induces Therapeutic Lymphangiogenesis in a Rat Model of Secondary Lymphoedema

F. Serizawa [a], K. Ito [b], M. Matsubara [c], A. Sato [a,*], H. Shimokawa [b], S. Satomi [a]

[a] *Division of Advanced Surgical Science and Technology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan*
[b] *Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan*
[c] *Division of Molecular Medicine, Centre for Translational and Advanced Animal Research, Tohoku University School of Medicine, Sendai, Japan*

Submitted 17 September 2010; accepted 5 February 2011

KEYWORDS
Shock wave therapy;
Lymphangiogenesis;
Lymphoedema

Abstract *Objective:* Lymphoedema is a common complication after cancer treatment. We have reported that low-energy extracorporeal shock wave (SW) therapy up-regulates vascular endothelial growth factor (VEGF) in ischaemic myocardium. As VEGF plays an important role in lymphangiogenesis, we investigated whether our low-energy SW therapy enhances lymphangiogenesis in rats.
Methods: We created a tail model of lymphoedema in rats. The tail was treated with or without low-energy SW therapy (0.25 mJ mm ^{2}, 500 impulses) four times (days 3, 5, 7, and 9). The tail volume and the fluorescence intensity of indocyanine green (ICG) were measured. The expression of VEGF-C and basic fibroblast growth factor (bFGF) were evaluated by RT-PCR, and the lymphatic vessel density was assessed histochemically.
Results: The tail volume increased significantly in the control group and was significantly improved in the SW group. The lymphatic system function (evaluated with fluorescence intensity of ICG), the lymphatic vessel density, and the expression of VEGF-C and bFGF were all enhanced by the SW therapy (all $P < 0.05$).
Conclusions: The low-energy SW therapy induces therapeutic lymphangiogenesis by up-regulating VEGF-C and bFGF, and improves lymphoedema in a rat-tail model, suggesting that low-energy SW therapy could be a non-invasive and effective strategy for lymphoedema in humans.

* Corresponding author. Tel.: +81 22 717 7214; fax: +81 22 717 7217.
E-mail address: attkas@med.tohoku.ac.jp (A. Sato).

1078-5884/$36
doi:10.1016/j.ejvs.2011.02.029

Please cite this article in press as: Serizawa F, et al., Extracorporeal Shock Wave Therapy Induces Therapeutic Lymphangiogenesis in a Rat Model of Secondary Lymphoedema, Eur J Vasc Endovasc Surg (2011), doi:10.1016/j.ejvs.2011.02.029

Lymphoedema occurs as a result of an imbalance between the demand for lymphatic flow and the capacity of the lymphatic circulation.[1] It is characterised by the regional accumulation of excess amounts of interstitial protein-rich fluid. Lymphoedema is a slowly progressive, usually painless swelling of the extremities. Primary lymphoedema is caused by developmental abnormalities of the lymphatic vessels. Secondary lymphoedema is the result of acquired obstruction of the lymphatic vessels and lymph nodes. Secondary lymphoedema is a major complication after surgery or radiation treatment for cancer, and the number of patients affected is increasing.[2,3] The standard treatments for lymphoedema are compression and manual drainage, which merely mitigate the symptoms. Therefore, new and effective therapies remain to be developed. Reconstructing the lymphatic circulation system is one promising strategy for lymphoedema.

We have previously demonstrated that low-energy extracorporeal shock wave (SW) therapy effectively induces therapeutic angiogenesis and improves myocardial ischaemia in pigs and humans as well as hindlimb ischaemia in rabbits, through up-regulation of vascular endothelial growth factor (VEGF).[4–8] VEGF-C plays an important and essential role in lymphangiogenesis.[9,10] Basic fibroblast growth factor (bFGF) can also induce lymphangiogenesis,[11,12] and its effect is mediated via VEGF-C and -D.[13] In the present study, we examined whether low-energy SW therapy improves lymphoedema in a rat model of tail lymphoedema and if so, whether VEGF and bFGF are involved.

Materials and Methods

Animals

Male Sprague-Dawley rats (CLEA Japan, Tokyo, Japan) weighing 200–250 g were used ($n = 90$). The animals were cared for in accordance with the principles and guidelines of the Japanese Ministry of the Environment. The protocols of the present study were approved by the ethics committee on animal experiments of Tohoku University (no. 22-303).

Secondary lymphoedema model in the rat

On day 1, we performed surgery to cause secondary lymphoedema in rat tails. The rat-tail model of secondary lymphoedema has been described previously.[14,15] Anaesthesia was induced with diethyl ether and maintained with the intra-peritoneal injection of pentobarbital (30 mg kg^{-1}) during surgery. Two parallel circumferential incisions were made 5 mm apart through the dermis, close to the tail base. The skin band and subcutaneous tissues, including lymphatic vessels, were removed completely. Lymphatic vessels were identified with the subcutaneous injection of 0.5% Evans blue dye. The major underlying blood vessels and tendon were preserved to prevent the distal tail from becoming necrotic. Both skin edges were cauterised with a radio knife for haemostasis and to delay wound closure. Postoperatively, the animals were randomly divided into the control and the SW groups. First, we treated 30 rats to measure tail volume; 15 for the control group and the remaining 15 for the SW group. On day 25, all animals were euthanised. Among them, 12 (six from each group) were used for RT-PCR analysis and another 12 for histochemical analysis; the remaining six were used for blood test. Second, we treated 48 rats (24 in each group) and euthanised 24 rats (12 from each group) on day 7 and 15, respectively. Among them, 12 (six from each group) were used for RT-PCR analysis and another 12 for histochemical analysis. Third, we treated additional 12 (six from each group) to evaluate lymphatic system function using indocyanine green (ICG) and an infrared camera. Thus, we used a total of 90 rats in this study.

Extracorporeal SW therapy

One SW treatment consisted of 0.25 mJ mm^{-2} (total energy flux density), 500 impulses, using a SW generator (DUOLITH® SD1; Storz Medical, Switzerland) based on our previous studies, in which maximal up-regulation of VEGF expression was achieved at ~0.1 mJ mm^{-2} (positive energy flux density).[4–8] According to the manufacturer, 0.1 mJ mm^{-2} (positive energy flux density) is equivalent to 0.25 mJ mm^{-2} (total energy flux density). Animals in the SW group received low-energy SW therapy to the surgical site four times (postoperative days 3, 5, 7 and 9), whereas those in the control group received the same procedures but without the SW treatment.

Tail volume measurement

Tail volume was measured using water displacement volumetry every 3 days ($n = 15$ per group).[16]

Evaluation of lymphatic system function

Lymphatic system function was evaluated by the ICG method ($n = 6$ per group). Briefly, we injected 0.1 mg of ICG (Daiichi Sankyo, Japan) subcutaneously in the end of the tail on day 1. As the injected ICG was absorbed in the lymphatic ducts and transported from the tail to the body, the fluorescence intensity gradually decreased. We evaluated the drainage function of lymphatic fluid by measuring the average fluorescence intensity with an infrared camera (PDE System® C9830; Hamamatsu Photonics, Japan) at the distal area of the surgical site every 2 days. The camera was fixed at 20 cm from the tail, and the measured area was 4.4 × 20 mm.

RT-PCR analysis

All tissues except bone were harvested from the surgical site on days 7, 15 or 25 ($n = 6$ per group). The samples were homogenised and used for total RNA extraction with a TRIzol® Plus RNA purification kit (Life Technologies Japan, Japan). RNA concentrations were determined using GeneQuant Pro® (Biochrome, UK). Reverse transcriptase M-MLV® (2640A, Takara Bio, Japan), three gene-specific primer pairs (Sigma–Aldrich Japan), and a LightCycler 2.0® (Roche Diagnostics, Tokyo, Japan) were used for PCR. The primers were as follows (5′ → 3′): for VEGF-C (286-bp fragment), GCCAATCACACT TCCTGCCG (sense) and CTGGCAGGTGTCTTCATCCAAC (antisense); for bFGF (225-bp fragment), CCAGTTGGTATGT GGCACTG (sense) and CAGGGAAGGGTTTGACAAGA (antisense); and for β-actin (612-bp fragment), ATATCGCTGC

Please cite this article in press as: Serizawa F, et al., Extracorporeal Shock Wave Therapy Induces Therapeutic Lymphangiogenesis in a Rat Model of Secondary Lymphoedema, Eur J Vasc Endovasc Surg (2011), doi:10.1016/j.ejvs.2011.02.029

GCTCGTC (sense) and TTTCCCTCTCAGCTGTGGT (anti-sense). The PCR conditions for VEGF-C were 40 cycles of 1 min at 94 °C, 90 s at 55 °C, and 90 s at 72 °C. The PCR conditions for bFGF were 40 cycles of 30 s at 94 °C, 60 s at 56 °C, and 105 s at 72 °C. The expression levels of the two genes were compared between the SW and control groups. Values are reported as the quotients of the copy number of the gene of interest relative to that of b-actin, as a housekeeping gene (VEGF-C/b-actin or bFGF/b-actin). The PCR reaction mixtures (20 μl) were separated electrophoretically in 2% agarose gels containing ethidium bromide, observed, and photographed under ultraviolet light.

Histochemical examination

The surgical site was excised, including 1 cm on each side on days 7, 15 or 25 ($n = 6$ per group). The samples were fixed with formalin, embedded in paraffin, and divided into two parts for staining: one with haematoxylin and eosin (HE) and the other with D2-40 (code: 413451, mouse monoclonal; Nichirei, Japan), an antibody against a lymphatic-specific marker.[17] We measured the thickness of the dermis and subcutaneous tissue just distal to the surgical site in the HE-stained samples (original magnification, ×200), and used the D2-40-stained samples to assess lymphatic vessel density (original magnification, ×400). The number of D2-40-positive vessels was counted in randomly selected microscopic fields, and the results are expressed as the number of D2-40-positive vessels/field. The observer counting the lymphatic vessels was blinded to treatment allocation of the rats. All histochemical examinations were performed with a BX51® microscope (Olympus, Japan).

Statistical analyses

Statistical analyses were performed with the unpaired *t*-test using StatMate 4. The results are expressed as means ± standard deviations (SDs). Differences were considered statistically significant at $P < 0.05$.

Results

Tail volume

Until day 4, the tail volume increased similarly in both groups. After day 4, the tail volume further increased in the control group, whereas it decreased in the SW group (Figs. 1 and 2). A significant difference in the tail volume was observed between the two groups from days 7–19 (day 10: 7.0 ± 0.8 vs. 8.4 ± 0.4 ml; day 19: 7.0 ± 0.6 vs. 8.2 ± 0.2 ml, both $P < 0.05$).

Lymphatic system function

The average fluorescence intensity value was significantly lower in the SW group than in the control group ($P < 0.05$) on days 7, 13, 23, and 25 (Fig. 3). These data indicate that the drainage of lymphatic fluid was enhanced by the SW therapy.

RT-PCR analysis

VEGF-C expression was significantly up-regulated in the SW group compared with the control group on days 7 and 15 (day 7: 1.52 ± 0.47 vs. 0.83 ± 0.14; day 15: 1.03 ± 0.02 vs. 0.54 ± 0.01, both $P < 0.05$), as was bFGF expression (day 7: 0.41 ± 0.21 vs. 0.15 ± 0.03; day 15: 1.01 ± 0.27 vs. 0.59 ± 0.05, both $P < 0.05$) (Fig. 4).

Histochemical examination

In the HE-stained histological specimens, the dermis and subcutaneous tissue of the control group were significantly swollen, as compared with the SW group, on days 7 and 15 (day 7: 408 ± 74 vs. 555 ± 45 mm; day 15: 371 ± 67 vs. 536 ± 60 mm, both $P < 0.05$) (Fig. 5). Upon immunostaining with D2-40, a specific marker of lymphatic vessels, newly formed lymphatic vessels were readily visualised in the subcutaneous tissue in the SW group. On days 15 and 25, the number of lymphatic vessels was significantly higher in the SW group than



Figure 1 Representative photographs of rat tails. On postoperative day 7, severe oedema and skin redness were observed in the control group whereas the edema in the SW group was modest.

Please cite this article in press as: Serizawa F, et al., Extracorporeal Shock Wave Therapy Induces Therapeutic Lymphangiogenesis in a Rat Model of Secondary Lymphoedema, Eur J Vasc Endovasc Surg (2011), doi:10.1016/j.ejvs.2011.02.029



Figure 2 Time course of tail volume. The SW therapy suppressed lymphedema. Up to day 4, lymphedema developed to a similar extent in both groups. On day 7, the tail volume had further increased in the controls, whereas it had started to decrease in the SW group. The difference in tail volume between the two groups was statistically significant from days 7–19.

in the control group (day 15: 4.2 ± 0.5 vs. 2.1 ± 0.7 per field; day 25: 4.8 ± 0.7 vs. 3.2 ± 0.8 per field, both $P < 0.05$) (Fig. 6).

Biochemical analysis

No significant differences were observed between two groups (total protein: 5.8 ± 0.12 vs. 5.8 ± 0.16; albumin 2.4 ± 0.04 vs. 2.3 ± 0.08). All results were shown in Table 1.

Discussion

The novel finding of the present study was that low-energy SW therapy induced effective therapeutic lymphangiogenesis in a rat model of secondary lymphoedema, and which was accompanied by the up-regulation of VEGF-C and bFGF.

Beneficial effects of SW therapy on lymphoedema

In the present study, the increased tail volume decreased significantly in the SW group with a significant increase in the number of D2-40-positive vessels at the site of surgery as compared with the control group. These results indicate that low-energy SW therapy enhanced lymphangiogenesis, thus reducing the lymphoedema. We also examined the removal rate of injected ICG from the distal part of the surgical site by measuring its fluorescence intensity with an infrared camera. Until day 5, the fluorescence intensity decreased similarly in both groups. The fluorescence intensity was significantly lower in the SW group than in the control group during the experimental period following SW therapy. These results indicate that low-energy SW therapy enhanced the drainage of lymphatic fluid. The fluorescence intensity in the control group also decreased between days 3 and 5 without any treatment, even though most of the superficial lymphatic system was removed by the surgery. Thus, it is possible that some ICG drained through the deep lymphatic vessels or diffused through deep tissues.

Mechanisms for the beneficial effects of SW therapy on lymphoedema

VEGF-C and bFGF are important factors for lymphangiogenesis.[9–12,18] VEGF-C gene transfer reduces lymphoedema in several animal models.[9,10,16] In the present study, the expression of VEGF-C and bFGF was enhanced significantly at the surgical site, where low-energy SW therapy was applied, suggesting that VEGF-C and bFGF were up-regulated by the low-energy SW therapy with a resultant therapeutic lymphangiogenesis. Recently, Kubo et al. also reported that low-energy SW therapy induced lymphangiogenesis and ameliorated secondary lymphoedema in rabbit-ear model.[19] They



Figure 3 Representative images of fluorescence intensity measurement (right) and the average fluorescence intensity (left). In the SW group, the average fluorescence intensity was lower than in the controls. The red arrows indicate the SW therapy.

Please cite this article in press as: Serizawa F, et al., Extracorporeal Shock Wave Therapy Induces Therapeutic Lymphangiogenesis in a Rat Model of Secondary Lymphoedema, Eur J Vasc Endovasc Surg (2011), doi:10.1016/j.ejvs.2011.02.029



Figure 4 Expression of VEGF-C and bFGF in a surgical site specimen. In the SW group, the expression of VEGF-C and bFGF was significantly enhanced on days 7 and 15, as compared with the control group.

evaluated the effects of SW therapy on skin thickness, expression of VEGF-C and VEGFR3, and lymphatic duct count. In both their and our studies, SW therapy reduced the increased skin thickness, up-regulated the expression of VEGF-C, and increased the lymphatic duct count. These results suggest that the SW therapy enhances up-regulation of VEGF-C leading to lymphangiogenesis. It is possible that the mechanical stress caused by the low-energy SW, such as cavitation (the formation of vapour bubbles in a flowing liquid) and shear stress,[20,21] induced VEGF-C and bFGF up-regulation. Further investigation is needed to clarify the detailed mechanisms of the beneficial effects of low-energy SW therapy.

Animal models of secondary lymphoedema

Several animal models of secondary lymphoedema have been reported, including rabbit-ear- and rat- or mouse-tail models.[14–16,19,22,23] In the present study, we used the rat-tail model because it allows precise measurements of the compartment volume. Pathologically, secondary lymphoedema results from a decreased transport capacity of the lymphatic system due to acquired lymphatic vessel or lymph node obstruction. The result of this condition is the stagnation of lymphatic fluid in the affected compartment, which is directly reflected in the compartment volume. Therefore, tail volume measurement would be superior to assessing skin thickness in evaluating the severity of lymphoedema. In fact, a heterogeneous distribution of lymphoedema in the same compartment is often observed in humans.[24]



Figure 5 Time course of subcutaneous tissue thickness. The SW therapy reduced the lymphedema compared with the control group.

Limitations

Several limitations of the present study should be mentioned. First, lymphoedema in the present rat-tail model might be different from that in humans. Rats have a powerful healing ability, and lymphoedema in the rat tail heals almost completely even with no treatment. By contrast, secondary lymphoedema in humans is always slowly progressive and does not recover naturally. No exact animal model of chronic secondary lymphoedema in humans is available. Nevertheless, the results of this study suggest that low-energy SW therapy may be effective, at least, in the acute phase of secondary lymphoedema in humans. Second, the optimal therapeutic condition is not clear. Low-energy SW therapy has been used to treat a variety of diseases, such as ischaemic heart disease, hindlimb ischaemia, and orthopaedic disorders; however, the doses and number of applications vary among studies (0.037–0.62 mJ mm^{-2}, 100–12 000 impulses).[4–8,19,25–29] Regarding the SW level, we have previously demonstrated that VEGF expression peaks at ~0.1 mJ mm^{-2} (positive energy flux density),[4,6] and according to the manufacturer, 0.1 mJ mm^{-2} (positive energy flux density) is equivalent to 0.25 mJ mm^{-2} (total energy flux density). Thus, in the present study, we employed 0.25 mJ mm^{-2}. Regarding the number of SW impulses, the most effective number of impulses is unknown for lymphoedema. However, in the clinical trial of the SW therapy for severe angina pectoris, satisfactory outcome was achieved with 4000–8000 impulses.[5,8] As the human heart (200–300 g) is about 15 times as heavy as the rat tail (15–20 g), we

Please cite this article in press as: Serizawa F, et al., Extracorporeal Shock Wave Therapy Induces Therapeutic Lymphangiogenesis in a Rat Model of Secondary Lymphoedema, Eur J Vasc Endovasc Surg (2011), doi:10.1016/j.ejvs.2011.02.029



Figure 6 Time course of lymphatic vessel density. The number of D2-40-positive vessels (red arrow) per field was increased significantly in the SW group as compared with the control group on days 15 and 25. Bar, 50 μm.

expected that 500 impulses may be enough to induce lymphangiogenesis. Regarding the number of treatment series, when we started the present study, we were not sure how many series of SW therapy were most effective. However, on day 7 (after two series of SW therapy), the tail volume began to decrease and the difference between the SW and the control groups became significant. On day 10 (after four series of SW therapy), significant difference became more clear. Thus, we considered that four series of SW therapy are sufficient for the present study. Further studies are required to find the optimal condition for each disease. Third, the number of rats used in this study might have been small for a well-grounded conclusion. Fourth, we must consider the anti-inflammatory effects of low-energy SW therapy. Because low-energy SW therapy suppresses inflammation,[30] it is possible that low-energy SW therapy could reduce lymphoedema through an anti-inflammatory effect as well.

Clinical implications

Although patients with lymphoedema suffer from physical and psychological impairments,[31,32] the available treatment options are limited. Traditional compression treatments with a bandage or manual lymph drainage are not curative. Lymphatico-venous anastomosis is effective for lymphoedema,[33,34] but is invasive and requires a surgeon skilled in microsurgery. Thus, it is desirable to develop a safe, non-invasive treatment for lymphoedema. In this study, we demonstrated that low-energy SW therapy ameliorated lymphoedema by enhancing lymphangiogenesis in rats. Furthermore, no side effects were observed. Because of no need for anaesthesia or invasive procedures, low-energy SW therapy might be suitable even for patients with severe lymphoedema that required repeated therapy. However, we need further consideration before clinical use because the rat-tail model is not exactly fit for the lymphoedema in humans.

Table 1 No significant differences were observed between two groups.

	Control (n = 3)	SW group (n = 3)
Total protein (g/dl)	5.8 ± 0.12	5.8 ± 0.16
Albumin (g/dl)	2.4 ± 0.04	2.3 ± 0.08
AST (I.U/l)	82 ± 10.6	84 ± 9.2
ALT (I.U/l)	31 ± 3.1	28 ± 3.3
HGB (g/dl)	15.4 ± 0.66	15.8 ± 0.71
Ht (%)	44.2 ± 1.00	44.4 ± 1.06

Conclusions

We demonstrated that low-energy SW therapy enhanced lymphangiogenesis and improved secondary lymphoedema in rats, suggesting that the low-energy SW therapy may have a potential to be a safe and non-invasive strategy for treating lymphoedema in humans.

Acknowledgements

The authors are grateful to Dr. Ernest H. Marlinghaus, Storz Medical AG, Switzerland, for invaluable comments on our study.

Conflict of Interest

None.

Funding

None.

References

1 Rockson SG. Lymphedema. *Am J Med* Mar 2001;**110**(4):288–95.
2 Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. *Gynecol Oncol* 2006;**103**(2):714–8.
3 Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. *Surg Oncol* 2006;**15**(3):153–65.
4 Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. *Circulation* 2004;**110**(19):3055–61.
5 Fukumoto Y, Ito A, Uwatoku T, Matoba T, Kishi T, Tanaka H, et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. *Coron Artery Dis* 2006;**17**(1):63–70.
6 Oi K, Fukumoto Y, Ito K, Uwatoku T, Abe K, Hizume T, et al. Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits. *Tohoku J Exp Med* 2008;**214**(2):151–8.
7 Ito K, Fukumoto Y, Shimokawa H. Extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy. *Tohoku J Exp Med* 2009;**219**(1):1–9.
8 Kikuchi Y, Ito K, Ito Y, Shiroto T, Tsuburaya R, Aizawa K, et al. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. *Circ J* 2010;**74**(3):589–91.
9 Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. *J Clin Invest* 2003;**111**(5):717–25.
10 Jiang D, Hu Y, Ling S. Expression of VEGF-C in rat cornea after alkali injury. *J Huazhong Univ Sci Technolog Med Sci* 2004;**24**(5): 483–5.
11 Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. *Trends Mol Med* 2002;**8**(10): 483–9.
12 Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. *Proc Natl Acad Sci USA* 2002; **99**(13):8868–73.
13 Chang LK, Garcia-Cardena G, Farnebo F, Fannon M, Chen EJ, Butterfield C, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. *Proc Natl Acad Sci USA* 2004;**101**(32):11658–63.
14 Saito Y, Nakagami H, Morishita R, Rutkowski JM, Moya M, Johannes J, et al. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. *Circulation* 2006;**114**(11): 1177–84.
15 Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA. Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. *Microvasc Res* 2006;**72**(3):161–71.
16 Liu Y, Fang Y, Dong P, Gao J, Liu R, Hhahbaz M, et al. Effect of vascular endothelial growth factor C (VEGF-C) gene transfer in rat model of secondary lymphedema. *Vascul Pharmacol* 2008;**48** (4–6):150–6.
17 Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. *Lab Invest* 2002;**82**(9):1255–7.
18 Shin JW, Min M, Larrieu-Lahargue F, Canron X, Kunstfeld R, Nguyen L, et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. *Mol Biol Cell* 2006;**17**(2):576–84.
19 Kubo M, Li TS, Kamota T, Ohshima M, Shirasawa B, Hamano K. Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis. *J Vasc Surg* 2010;**52**(2):429–34.
20 Ogden JA, Toth-Kischkat A, Schultheiss R. Principles of shock wave therapy. *Clin Orthop Relat Res* 2001;(387):8–17.
21 Maisonhaute E, Prado C, White PC, Compton RG. Surface acoustic cavitation understood via nanosecond electrochemistry. Part III: shear stress in ultrasonic cleaning. *Ultrason Sonochem* 2002;**9**(6):297–303.
22 Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. *FASEB J* 2002;**16**(14):1985–7.
23 Fu K, Izquierdo R, Vandevender D, Warpeha RL, Fareed J. Transplantation of lymph node fragments in a rabbit ear lymphedema model: a new method for restoring the lymphatic pathway. *Plast Reconstr Surg* 1998;**101**(1):134–41.
24 Ancukiewicz M, Russell TA, Otoole J, Specht M, Singer M, Kelada A, et al. Standardized method for quantification of developing lymphedema in patients treated for breast cancer. *Int J Radiat Oncol Biol Phys*; Jun 2 2010.
25 Ito Y, Ito K, Shiroto T, Tsuburaya R, Yi GJ, Takeda M, et al. Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. *Coron Artery Dis* 2010;**21**(5):304–11.
26 Saggini R, Figus A, Troccola A, Cocco V, Saggini A, Scuderi N. Extracorporeal shock wave therapy for management of chronic ulcers in the lower extremities. *Ultrasound Med Biol* 2008;**34** (8):1261–71.
27 Wang CJ, Kuo YR, Wu RW, Liu RT, Hsu CS, Wang FS, et al. Extracorporeal shockwave treatment for chronic diabetic foot ulcers. *J Surg Res* 2009;**152**(1):96–103.
28 Xu ZH, Jiang Q, Chen DY, Xiong J, Shi DQ, Yuan T, et al. Extracorporeal shock wave treatment in nonunions of long bone fractures. *Int Orthop* 2009;**33**(3):789–93.
29 Uwatoku T, Ito K, Abe K, Oi K, Hizume T, Sunagawa K, et al. Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs. *Coron Artery Dis* 2007;**18**(5):397–404.
30 Rompe JD, Rumler F, Hopf C, Nafe B, Heine J. Extracorporal shock wave therapy for calcifying tendinitis of the shoulder. *Clin Orthop Relat Res* 1995;(321):196–201.
31 Vassard D, Olsen MH, Zinckernagel L, Vibe-Petersen J, Dalton SO, Johansen C. Psychological consequences of lymphoedema associated with breast cancer: a prospective cohort study. *Eur J Cancer*; Aug 24 2010.
32 Chachaj A, Malyszczak K, Pyszel K, Lukas J, Tarkowski R, Pudelko M, et al. Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment. *Psychooncology* 2010;**19**(3):299–305.
33 Campisi C, Bellini C, Accogli S, Bonioli E, Boccardo F. Microsurgery for lymphedema: clinical research and long-term results. *Microsurgery* 2010;**30**(4):256–60.
34 Boccardo F, Casabona F, De Cian F, Friedman D, Villa G, Bogliolo S, et al. Lymphedema microsurgical preventive healing approach: a new technique for primary prevention of arm lymphedema after mastectomy. *Ann Surg Oncol* 2009;**16**(3): 703–8.

Please cite this article in press as: Serizawa F, et al., Extracorporeal Shock Wave Therapy Induces Therapeutic Lymphangiogenesis in a Rat Model of Secondary Lymphoedema, Eur J Vasc Endovasc Surg (2011), doi:10.1016/j.ejvs.2011.02.029